Navigation Links
New Interim Analysis From Observational Study Suggests That Delivery Of Insulin Via Valeritas' V-Go Shows Promise In Improving Glycemic Control For Patients With Type 2 Diabetes
Date:5/2/2013

ny magnetic resonance imaging (MRI) testing.

About Valeritas, Inc.

Valeritas is committed to developing and commercializing innovative treatment solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of Type 2 diabetes. Valeritas' portfolio is headlined by the V-Go® disposable insulin delivery device, which is being commercialized and reimbursed in a specialty pharmaceutical model and is distributed through retail pharmacy.

V-Go meets an adult Type 2 diabetes patient's insulin needs by providing a treatment that is simple, convenient and easy to use. V-Go mimics the insulin pattern of the body (when used according to the Instructions for Patient Use) by providing a continuous preset basal rate of insulin over 24 hours and on-demand bolus dosing at mealtimes.

Valeritas' development portfolio also includes the h-Patch™ technology for the delivery of other compounds beyond insulin, the Mini-Ject™ Pre-Filled Needle-Free Delivery System, and the Micro-Trans™ Microneedle Transdermal Delivery Patch. These technologies, not commercially available, when combined with certain compounds, are designed to provide unique products that allow precise dosing in previously difficult to treat conditions.

In March 2011, Valeritas received EU CE Mark approval for V-Go. In November 2012, Valeritas was named Life Science Company of the year by the New Jersey Technology Council for its targeted mission and focus on the development of technology to improve the lives of people with Type 2 diabetes. Its Executive Management Team was further recognized for the ability to effectively develop and commercialize devices at high volumes. In addition, Valeritas received the 2012 Scrip Financing of the Year award for raising $150 million in Series C financing in September 2011.

Headquartered in Bridgewater, New Jersey, Valeritas operat
'/>"/>

SOURCE Valeritas, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
2. Interim Results Reported for Phase I Open-Label Clinical Trial for the Treatment of PTSD and MDD Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
3. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
4. Psyadon Announces Positive Interim Analysis of Phase 2 Study of Ecopipam for the Treatment of Tourette Syndrome
5. IRIDEX Appoints Chairman William M. Moore as Interim President & CEO
6. Sihuan Pharmaceutical Announces 2012 Interim Results
7. Medical Marijuana Inc. Announces Ted Caligiuri as Interim President and CEO
8. XBiotech Reports Positive Phase II Interim Analysis Results From Type 2 Diabetes Study
9. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
10. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
11. XBiotech Reports Positive Phase II Interim Analysis Results in Vascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 1, 2015 Ardelyx, Inc. (NASDAQ: ... gastrointestinal and cardio-renal diseases, today announced that Sanofi ... and license agreement for Ardelyx,s portfolio of NaP2b ... payment associated with termination and the return of ... Sanofi entered into an option and license agreement ...
(Date:9/1/2015)... Sept. 1, 2015  Dynatronics Corporation (NASDAQ: ... at the First Annual Ladenburg Thalmann Healthcare Conference ... Kelvyn H. Cullimore, Jr. , Chairman and ... investment representatives on Tuesday, September 29 at 10:30 ... Conference will showcase leading-edge companies in the healthcare ...
(Date:9/1/2015)... -- Dr. Cindy Orser , the Chief Science Officer ... of DigiPath, Inc. (OTCQB: DIGP), was recently interviewed ... consistency in today,s medical cannabis testing industry. In her ... she explained that the state-to-state variations in cannabis laws ... makes standardization impossible. Dr. Orser is ...
Breaking Medicine Technology:Ardelyx Regains NaP2b Program from Sanofi 2Ardelyx Regains NaP2b Program from Sanofi 3DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 3
... China , April 29 /PRNewswire-Asia-FirstCall/ -- China Pharma,Holdings, Inc. (NYSE ... pharmaceuticals company in China , today announced,that it has retained CCG ... , , ... to working with CCG to establish more effective and,transparent communications channels with ...
... , April 29 Royal Philips Electronics ( ... provider of integration solutions in healthcare, to deploy the Orion Health Rhapsody® ... , , ... , , ...
Cached Medicine Technology:China Pharma Holdings, Inc. Retains CCG Investor Relations 2China Pharma Holdings, Inc. Retains CCG Investor Relations 3China Pharma Holdings, Inc. Retains CCG Investor Relations 4China Pharma Holdings, Inc. Retains CCG Investor Relations 5Philips and Orion Health Partner to Deliver on Enterprise Interoperability 2Philips and Orion Health Partner to Deliver on Enterprise Interoperability 3Philips and Orion Health Partner to Deliver on Enterprise Interoperability 4
(Date:9/1/2015)... ... September 01, 2015 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... its annual Light it Red for Lymphoma awareness initiative, the nation’s premier and ...
(Date:9/1/2015)... ... ... From Aug. 17-21, Calvary Hospital hosted the 18th consecutive session of its ... taken place at Kingsborough Community College in Brooklyn in each of the past three ... and two junior counselors who were campers themselves just a few years ago. , ...
(Date:9/1/2015)... ... September 01, 2015 , ... Georgia State University ... across the country in stemming sexual assaults on their campuses. , The free, ... consortium of sexual assault researchers and student affairs professionals responding to calls by ...
(Date:9/1/2015)... ... September 01, 2015 , ... As part ... and Blue Shield of Minnesota (Blue Cross) has announced Doctor On Demand as ... San Francisco, Doctor On Demand provides immediate access to Board Certified physicians or ...
(Date:9/1/2015)... Fairfax, VA (PRWEB) , ... September 01, 2015 ... ... the Mane Vendor “Hair Extension Vending Machine,” is still strongly maintaining her firm’s ... modern technology, and beauty tools. In her upcoming city-to-city tour, Ellis will be ...
Breaking Medicine News(10 mins):Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 2Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 3Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:Georgia State, Partners Introduce Climate Survey to Aid in Preventing Campus Sexual Assaults 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2
... the Flexible-Fiber CO2 laser to safely cut and coagulate ... sight problems encountered with conventional CO2 lasers. The findings, ... Boston University School of Medicine (BUSM), appear in the ... the first study to report the utility of flexible-fiber ...
... August 16, 2011 Seattle Children,s Research Institute ... million grant from the Bill & Melinda Gates ... respiratory support device, called Seattle Children,s Positive Airway ... affordable and simple Bubble Continuous Positive Airway Pressure ...
... , TUESDAY, Aug. 16 (HealthDay News) -- Many women ... supplement that,s been recalled due to dangerous ingredients, a new ... and phenolphthalein, both of which are banned in the United ... and cancer. The U.S. Food and Drug Administration announced ...
... , MONDAY, Aug. 15 (HealthDay News) -- You ... new study suggests. Japanese researchers report that alcohol hinders ... study of 10 male university students, appear online and in ... & Experimental Research . Booze,s effect on sleep ...
... 2011 Updated public standards incorporating new tests for ... ensure the quality of over-the-counter (OTC) ingredients and products ... 8-9, 2011, workshop co-sponsored by the U.S. Food & ... In addition to providing updates on new ...
... HealthDay Reporter , MONDAY, Aug. 15 (HealthDay News) -- Psychologists ... that places a high value on defending one,s reputation at ... with high rates of accidental deaths. "People who embrace ... Ryan Brown, an associate professor of psychology at the University ...
Cached Medicine News:Health News:Study finds flexible-fiber CO2 laser safe in endoscopic endonasal transsphenoidal surgery 2Health News:Seattle Children's lands major funding with hopes of saving thousands of infant lives 2Health News:Seattle Children's lands major funding with hopes of saving thousands of infant lives 3Health News:U.S. Women Using Dangerous Weight-Loss Pill 2 Years After Recall 2Health News:More Evidence That Alcohol Hinders Good Sleep 2Health News:FDA-USP workshop to preview updated OTC standards 2Health News:FDA-USP workshop to preview updated OTC standards 3Health News:For Men, 'Culture of Honor' Can Be Deadly 2Health News:For Men, 'Culture of Honor' Can Be Deadly 3
The Rheumatoid Factor (RF) assay is used for the quantitative analysis of rheumatoid factor in human serum....
Rheumatoid Factor , R1: 4 X 20 ml buffer, R2: 2 X 8 ml antibody, Test / Kit: 320 (H717)...
EXTEND is an absorbable synthetic punctal implant that provides occlusion up to three months. It is packaged 20 implants per box in sizes of .0.3mm, 0.4mm, 0.5mm. A variety pack in also available w...
... The Carriazo-Pendular microkeratome is based ... of the cornea during the cut., ... applanated evenly from the beginning of ... ensures that the intraocular pressure does ...
Medicine Products: